Literature DB >> 2317259

Anti-tumour imidazotetrazines. Part XXI. Mitozolomide and temozolomide: probes for the major groove of DNA.

A S Clark1, M F Stevens, C E Sansom, C H Schwalbe.   

Abstract

The structural and electronic properties of the major groove-binding anti-tumour imidazotetrazinones, mitozolomide and temozolomide were studied using molecular orbital techniques. Structure-activity relationships of mitozolomide derivatives emphasized the importance of a hydrogen bond donor on the C8-substituent and showed that good activity would be expected for derivatives carrying a small C8-substituent with restricted negative potential. The coplanarity of the carboxamide substituent in mitozolomide is unlikely to be disrupted by hydrogen bonding in the major groove. Semi-empirical M.O. calculations gave a very high partial positive charge on C4, indicating an enhanced susceptibility to nucleophilic attack leading to ring opening at this position and the formation of a triazene alkylating agent.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317259

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  4 in total

1.  Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity.

Authors:  L L Tsang; P B Farmer; A Gescher; J A Slack
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Population pharmacokinetics of temozolomide in cancer patients.

Authors:  J F Jen; D L Cutler; S M Pai; V K Batra; M B Affrime; D N Zambas; S Heft; G Hajian
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

3.  Design and mechanism of action of a novel cytotoxic 1,2,3-triazene-containing heterocycle, 3,5-dimethyl-pyrido-1,2,3,5-tetrazepin-4-one (PYRZ), in the human epithelial ovarian cancer cell line NIH:OVCAR-3 in vitro.

Authors:  B J Jean-Claude; A Mustafa; N D Cetateanu; Z Damian; J De Marte; R Yen; D Vasilescu; T H Chan; B Leyland-Jones
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.

Authors:  Nausicaa Clemente; Benedetta Ferrara; Casimiro Luca Gigliotti; Elena Boggio; Maria Teresa Capucchio; Elena Biasibetti; Davide Schiffer; Marta Mellai; Laura Annovazzi; Luigi Cangemi; Elisabetta Muntoni; Gianluca Miglio; Umberto Dianzani; Luigi Battaglia; Chiara Dianzani
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.